
November 24, 2021

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400051

Code: CADILAHC

Sub.: Intimation under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Re.: Cadila Healthcare Ltd., enters into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine

Dear Sir / Madam,

This is to inform you that Cadila Healthcare Ltd. (CHL), has entered into a manufacturing license and technology transfer agreement for its Plasmid DNA based Covid-19 (ZyCoV-D[®]) vaccine with Enzychem Lifesciences (KOSDAQ:183490) (Enzychem) of Republic of Korea. CHL will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences. Both CHL and Enzychem believe that this partnership will lead to an estimated manufacturing of 80 million or more doses of the Plasmid DNA vaccine in 2022. Under the agreement, Enzychem will manufacture and commercialise the vaccine within its territory under a Zydus trademark and CHL will receive the license fees and royalty payments for the same.

ZyCoV-D[®] is the first DNA plasmid vaccine in the world for human use, developed indigenously by CHL against the Covid-19 virus. The vaccine is administered intradermally using the PharmaJet[®] needle free applicator, which ensures painless intradermal vaccine delivery.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Ltd., said "We are very happy to partner with Enzychem Lifesciences and provide access to the technology behind the needle-free, Plasmid DNA vaccine technology which is the first of its kind in the world. Our aim is to provide new innovations and novel technologies that can support people with better approaches to healthcare. This agreement enables people in South Korea and other key markets of Enzychem, the access to a safe, well tolerated and efficacious vaccine with a novel platform to fight COVID-19."

Mr. Ki Young Sohn, Chairman of Enzychem Lifesciences said: "Today marks an important milestone for our vaccine consortium as we embark on the manufacturing of the world's first in-class DNA vaccine for humans. This technology allows vaccines to be produced at affordable costs in record times, and DNA vaccines are considerably stable. ZyCoV-D is administered without needles and can be deployed more readily, especially in resource-poor populations where these are urgently needed". "With state-of-the-art manufacturing facilities and a qualified workforce dedicated to manufacturing high quality

products, we are very eager to partner with Zydus in addressing the global demand for COVID vaccines, especially in low-medium income countries.”

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.

About Enzychem Lifesciences

Headquartered in Seoul, South Korea, Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases.

Please bring the aforesaid update to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY